We demonstrated up-regulation of several phosphodiesterases, including PDE5, the therapeutic target of medical therapy for pulmonary hypertension, which works to inhibit PDE5, thereby increasing cGMP and vasodilation. Here, PDE5A is linked to pulmonary hypertension.